Skip to Content

Nivolumab plus cabozantinib as first-line treatment for patients with aRCC – Final results 

CHECKMATE 9ER TRIAL: After a 2-year follow-up period the final overall survival analysis and updated results on efficacy and safety are ready to be presented at ASCO GU 2022.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top